Digitalization has affected many sectors, and healthcare is no exception. At the heart of this shift, the pharmaceutical supply chain has undergone profound changes, positively impacting several aspects.

Enhanced traceability ensures safety

One impact of digitalization on the supply chain has been a significant improvement in medication traceability. Thanks to technology, it is now possible to track a medication from production to patient administration. Among other things, this has led to:

• Improved health safety,
• Optimized inventory management,
• Greater regulatory compliance,

Strengthened collaboration among supply chain stakeholders

The digitalization of healthcare has facilitated collaboration among supply chain stakeholders.

• Secure data exchange: Digital platforms enable the secure sharing of information between manufacturers, distributors, pharmacies, and hospitals.
• Improved communication: Online collaboration tools facilitate communication and decision-making.

However, digitalization has not had solely positive impacts on the supply chain; it has also created a number of challenges for the pharmaceutical sector to address.

Key considerations include :

• Data security: Protecting health data is a major issue.
• Investment costs: Implementing IT systems can entail significant costs.

While the digitalization of the pharmaceutical supply chain has certainly had positive impacts, it is important that we address the various challenges it creates.

The lifecycle of a drug-from conception to commercialization, including manufacturing and distribution—is a complex and strictly regulated process. Each stage of this journey is essential to ensuring the safety and efficacy of the treatments administered to patients.

The various phases of the medication management cycle

The medication management cycle can be divided into several key phases.

Research and Development

This phase begins with the identification of a new molecule or active substance, followed by a series of laboratory and animal model tests to evaluate its therapeutic potential and toxicity.

Production

Once clinical trials are successfully completed, the drug is manufactured on a large scale in pharmaceutical plants, adhering to strict quality standards.

Commercialization

After obtaining marketing authorization, the drug is distributed to pharmacies and hospitals.

Post-marketing surveillance

Even after it is marketed, the drug continues to be monitored to detect potential long-term adverse effects and to evaluate its efficacy in broader populations.

The importance of safety and efficacy

The safety and efficacy of a medicine are two essential criteria for ensuring the protection of public health. To achieve this balance, health authorities implement strict regulations and rigorous monitoring procedures throughout the medicine’s lifecycle.

The safety of a medicine is ensured through :

• Rigorous clinical trials to evaluate potential risks and benefits.
• Continuous monitoring of adverse effects.
• Effective pharmacovigilance systems.

The efficacy of a medicine is demonstrated by :

• Rigorous clinical trials to prove the drug’s efficacy in treating a specific disease.
• Post-marketing studies to confirm long-term efficacy.

Key issues in medication management

Medication management is a major public health issue. It involves numerous stakeholders, such as pharmaceutical companies, health authorities, healthcare professionals, and patients. The key challenges of this management are :

• Quality of medicines
• Access to medicines
• Combating antimicrobial resistance

The medication management cycle is a complex process requiring close coordination among all stakeholders involved. By ensuring the safety and efficacy of medications, we contribute to improving public health and extending life expectancy.

Access to medicines is a major global public health issue. While developed countries benefit from generally high-performing healthcare systems and an abundant supply of medicines, the situation is very different in developing countries. The latter face numerous challenges that limit their populations’ access to essential medicines.

The main obstacles to accessing medicines in developing countries

Several factors underlie the difficulties populations in developing countries face in accessing essential medicines.

• Cost of medicines : High drug prices-particularly for innovative medicines—pose a major challenge for the healthcare budgets of developing countries.
• Healthcare infrastructure : A lack of adequate healthcare infrastructure, such as hospitals, pharmacies, and cold-chain facilities for temperature-sensitive medicines, complicates drug distribution.
• Availability of medicines : Stockouts are frequent, especially for essential medicines, due to logistical, regulatory, or production issues.
• Social inequalities : The poorest populations are often the most affected by a lack of access to medicines, owing to their limited purchasing power and distance from healthcare facilities.

Naturally, this has consequences at various levels.

The consequences of a lack of access to essential medicines

The consequences are varied.

• Increased morbidity and mortality : Many diseases—particularly infectious ones—cannot be effectively treated without access to appropriate medicines.
• An economic burden : Untreated illnesses can lead to complications and costly hospitalizations, driving up healthcare spending in the affected countries.
• Reduced productivity : Untreated illnesses can diminish individuals’ capacity to work, thereby hindering national economic development.

While solutions have been implemented and the issue remains a subject of debate, more work needs to be done. By improving access to medicines, developing countries can enhance the health of their populations and foster economic development.